DK1912673T3 - Fremgangsmåde til at binde effektor-molekyler til proteiner - Google Patents

Fremgangsmåde til at binde effektor-molekyler til proteiner

Info

Publication number
DK1912673T3
DK1912673T3 DK06744294.7T DK06744294T DK1912673T3 DK 1912673 T3 DK1912673 T3 DK 1912673T3 DK 06744294 T DK06744294 T DK 06744294T DK 1912673 T3 DK1912673 T3 DK 1912673T3
Authority
DK
Denmark
Prior art keywords
protein
effector molecules
proteins
binding effector
cysteines
Prior art date
Application number
DK06744294.7T
Other languages
English (en)
Inventor
Sam Philip Ucb Celltech Heywood
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of DK1912673T3 publication Critical patent/DK1912673T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Catalysts (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Jellies, Jams, And Syrups (AREA)
DK06744294.7T 2005-07-06 2006-06-29 Fremgangsmåde til at binde effektor-molekyler til proteiner DK1912673T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0513852.4A GB0513852D0 (en) 2005-07-06 2005-07-06 Biological products
PCT/GB2006/002416 WO2007003898A1 (en) 2005-07-06 2006-06-29 Process for attaching effector molecules to proteins

Publications (1)

Publication Number Publication Date
DK1912673T3 true DK1912673T3 (da) 2011-05-02

Family

ID=34856761

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06744294.7T DK1912673T3 (da) 2005-07-06 2006-06-29 Fremgangsmåde til at binde effektor-molekyler til proteiner

Country Status (15)

Country Link
US (1) US8378073B2 (da)
EP (1) EP1912673B1 (da)
JP (1) JP5203188B2 (da)
CN (1) CN101212984B (da)
AT (1) ATE502650T1 (da)
AU (1) AU2006264684B2 (da)
CA (1) CA2613481C (da)
DE (1) DE602006020878D1 (da)
DK (1) DK1912673T3 (da)
ES (1) ES2361096T3 (da)
GB (1) GB0513852D0 (da)
PL (1) PL1912673T3 (da)
PT (1) PT1912673E (da)
SI (1) SI1912673T1 (da)
WO (1) WO2007003898A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009205995B2 (en) * 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
CN102741287B (zh) 2009-02-17 2015-02-18 Ucb制药公司 对人ox40具有特异性的抗体分子
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2013004844A1 (en) 2011-07-07 2013-01-10 Novo Nordisk A/S Drug delivery injection pen with add-on dose capturing and display module
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
US11219690B2 (en) 2013-12-13 2022-01-11 Novo Nordisk Healthcare Ag Method for thioether conjugation of proteins
CA3211226A1 (en) * 2014-02-11 2015-08-20 Seagen Inc. Selective reduction of proteins
GB201419184D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
SG11201704841UA (en) * 2014-12-22 2017-07-28 Ucb Biopharma Sprl Method of protein manufacture
CN107708679A (zh) 2015-06-04 2018-02-16 安特里阿比奥有限公司 用于制备位点特异性蛋白质偶联物的胺聚乙二醇化方法
CA3052539C (en) * 2017-02-08 2022-08-30 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
MX2023006650A (es) 2020-12-07 2023-06-21 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos.
JP2023551983A (ja) 2020-12-07 2023-12-13 ユーシービー バイオファルマ エスアールエル インターロイキン-22に対する抗体
EP4334355A1 (en) 2021-05-03 2024-03-13 UCB Biopharma SRL Antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728430A (en) * 1986-02-10 1988-03-01 Millipore Corporation Diafiltration method
US5216183A (en) * 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
US5225194A (en) * 1989-11-13 1993-07-06 Ldc Research Corporation Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases
AU1140495A (en) 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
AU1604800A (en) * 1998-10-30 2000-05-22 Nephros, Inc. Non-isosmotic diafiltration system
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6406631B1 (en) * 1999-07-30 2002-06-18 Nephros, Inc. Two stage diafiltration method and apparatus
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CN1621091A (zh) * 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US7908694B1 (en) * 2008-09-24 2011-03-22 Robert Sloane Mattress cover apparatus with integrated seals

Also Published As

Publication number Publication date
ATE502650T1 (de) 2011-04-15
PT1912673E (pt) 2011-04-14
GB0513852D0 (en) 2005-08-10
AU2006264684B2 (en) 2011-11-03
CN101212984B (zh) 2011-09-28
WO2007003898A1 (en) 2007-01-11
CA2613481A1 (en) 2007-01-11
ES2361096T3 (es) 2011-06-13
JP2008544976A (ja) 2008-12-11
US20080306246A1 (en) 2008-12-11
JP5203188B2 (ja) 2013-06-05
EP1912673B1 (en) 2011-03-23
CA2613481C (en) 2014-11-25
AU2006264684A1 (en) 2007-01-11
WO2007003898A8 (en) 2008-10-09
DE602006020878D1 (de) 2011-05-05
CN101212984A (zh) 2008-07-02
EP1912673A1 (en) 2008-04-23
US8378073B2 (en) 2013-02-19
PL1912673T3 (pl) 2011-07-29
SI1912673T1 (sl) 2011-10-28

Similar Documents

Publication Publication Date Title
DK1912673T3 (da) Fremgangsmåde til at binde effektor-molekyler til proteiner
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
ATE517917T1 (de) Herstellung eines rekombinanten il-18-bindenden proteins
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
MY174493A (en) Binding agents
BRPI0508610A (pt) derivados de aminoácidos
DK1951747T3 (da) Fremgangsmåde og mellemprodukter til syntese af caspofungin
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA200802054A1 (ru) Ингибиторы фермента
DE602006009789D1 (de) Acetylenderivate
EA200702193A1 (ru) Гликозилирование белков
NO20082749L (no) Fremgangsmate for fremstilling av ferri-succinylkasein
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
ZA200800862B (en) Cross-β structure binding compounds
DE602006019870D1 (de) Verfahren zur synthese von triazolen
EA200701852A1 (ru) Производные аминокислот
ATE529433T1 (de) Verfahren zur reinigung eines il-18-bindenden proteins
NO20082989L (no) Fremstiling av gamma-aminosyrer som har affinitet for alfa-2-deltaproteinet
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
EA200870058A1 (ru) Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
TW200740769A (en) Novel process
ATE458482T1 (de) Verwendung von amino substituierten benzimidazolen
ITRM20050425A1 (it) Processo per la produzione di prodotti a base di idrolizzati proteici in composizione con manganese.
CY1109747T1 (el) Μεθοδος διεργασιων για την παρασκευη αναστολεων τρυπτασης